Article Excerpt: Digital health companies are going through an interesting transformation as research institutions realize the benefit of their technology to collect and manage data for a host of studies. The biopharma industry’s embrace of some digital health tools to manage the costs of drug development has led to more frequent collaborations with research institutions, particularly in the behavioral health space. It’s not surprising since mental health can influence medication adherence, which can undermine a drug’s effectiveness, but that’s not the only factor at play. There’s also the great hunt for biomarkers and other clues that cognitive assessments can provide in piecing together data that can lead to earlier interventions from depression to schizophrenia.
Full Article: http://tinyurl.com/ybrgh5ul
Article Source: MedCity News